Clinical trials
Opioid Use Disorder, Moderate clinical trials
Below are recruiting opioid use disorder, moderate clinical trials, each written for real people, not researchers. We’re tracking 82 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05589181RecruitingPhase 3
High-dose buprenorphine start in the emergency department for fentanyl use
This Phase 3 study tests whether starting a high dose of buprenorphine in the emergency department helps people with opioid use disorder come through withdrawal more safely and effectively. It focuses on people whose urine test shows fentanyl and who are already in withdrawal when they arrive.
Newark, New JerseyAges 18 years+ - NCT06136247Recruiting
Brain & thinking tests in opioid use disorder
This study tests whether brain scans and thinking tests can help understand opioid use disorder. It is for people on stable buprenorphine or methadone treatment.
Philadelphia, PennsylvaniaAges 18–60 - NCT06306443RecruitingPhase 3
Buprenorphine treatment for people leaving jail
This trial offers buprenorphine (a medication for opioid use disorder) to people in jail who are soon to be released. It helps you start treatment while incarcerated and continue it after you return to the community, aiming to reduce overdose and improve recovery.
Baltimore, MarylandAges 18 years+ - NCT06494904RecruitingPhase 3
Standard vs. High Dose Buprenorphine in the ER
This study compares a higher dose of buprenorphine (a medicine that helps stop opioid cravings and withdrawal) to the usual dose, given in the emergency department. It aims to see if the higher dose works better to start treatment for opioid use disorder.
Oakland, CaliforniaAges 18–65 - NCT04161066RecruitingPhase 1
Psilocybin plus buprenorphine to help opioid use disorder symptoms
This Phase 1 study tests how adding psilocybin to a standard opioid treatment (buprenorphine-naloxone) affects recovery and symptoms in people with moderate-to-severe opioid use disorder. It may help researchers understand whether this combination is safe and beneficial alongside medication for opioid withdrawal and cravings.
Madison, WisconsinAges 21–65 - NCT06786325RecruitingPhase 2
Psilocybin treatment study for opioid use disorder
This trial tests whether psilocybin can help people recovering from opioid use disorder while living at a residential treatment center. If you are already taking buprenorphine/naloxone (Suboxone), methadone, or have received Sublocade, this study may be an option for you.
Philadelphia, PennsylvaniaAges 18–60 - NCT06799117Recruiting
Decision Support for Opioid Addiction Treatment
This study tests a new way to help people in the emergency department who have moderate to severe opioid use disorder. It looks at using a decision-support tool to guide treatment choices.
Guilford, ConnecticutAges 18 years+ - NCT06810310RecruitingPhase 2
Psilocybin for motivation in opioid use disorder
This study tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) can help people with opioid use disorder stay motivated in recovery. It uses brain scans to see how psilocybin affects brain areas linked to motivation.
Philadelphia, PennsylvaniaAges 18–60 - NCT06877858RecruitingPhase 1
MethaLoad dose-finding study for opioid use disorder
This study tests a new way to start methadone treatment (called 'MethaLoad') for people with opioid use disorder who have used fentanyl. If you qualify, you will receive methadone to help manage withdrawal and reduce cravings, and the doctors will closely monitor your safety and response.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07262190Recruiting
NavSTAR program for opioid use disorder
This trial tests a program to help people with opioid use disorder start or continue treatment while in the hospital. It aims to connect patients to care after they leave.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06405607RecruitingPhase 2
Psilocybin vs Ketamine for Alcohol Use Disorder Trial
This trial tests two psychedelic-assisted therapies, psilocybin and ketamine, to see which works better for reducing heavy drinking in people with alcohol use disorder (AUD). You'll receive either drug along with counseling, and the study monitors safety closely.
Iowa City, IowaAges 21–65 - NCT06484075RecruitingPhase 1/Phase 2
Suvorexant for alcohol use disorder: brain effects
This study tests whether the sleep medication suvorexant can help people with alcohol use disorder by looking at its effects on brain activity. Participants will stay in the hospital for about a month, take suvorexant or a placebo, and have brain scans.
Bethesda, MarylandAges 18–75 - NCT05538910Recruiting
Study brain links between depression and substance use
This study uses brain imaging and questionnaires to understand how substance use and depression are connected in the brain. It may help researchers identify biological patterns that could guide better treatments in the future.
Baltimore, MarylandAges 18–60 - NCT05525598Recruiting
Online therapy for severe body–mind symptom disorders
This trial tests an internet-based treatment program for people with moderate-to-severe functional somatic disorders (long-lasting physical symptoms linked to how the body and brain interact). It may help reduce symptoms and improve day-to-day functioning by offering structured support online.
Aarhus C, DenmarkAges 18–60 - NCT06788587RecruitingPhase 2
Long-term stimulant for methamphetamine recovery
This study tests whether a high dose of a stimulant medication (lisdexamfetamine, an ADHD medicine) taken over many weeks can help people who have already completed a methamphetamine treatment program to stay off meth, reduce use, or avoid relapse.
Montreal, QuebecAges 18–55 - NCT07040592RecruitingPhase 2
Semaglutide for HIV and alcohol use
This study is testing whether semaglutide, a medication already used for diabetes and weight loss, can help people with HIV who also have an alcohol use disorder cut back on drinking. It is for patients treated at the Atlanta VA Healthcare System.
Decatur, GeorgiaAges 18–99 - NCT06470698Recruiting
Using emotional awareness to predict treatment success in addiction
This trial tests whether tracking emotional awareness can help predict how well people recover from cocaine or alcohol addiction. It uses a mobile app to monitor feelings and progress.
HuelvaAges 18 years+ - NCT06030154Recruiting
Boosting positive feelings for people with alcohol use disorder
This study tests a program designed to help people with alcohol use disorder who also struggle with low mood or anxiety. It aims to increase positive emotions, which may make it easier to reduce drinking.
Tulsa, OklahomaAges 18–65 - NCT06218056RecruitingPhase 2
CBD for reducing cigarette smoking in a treatment center
This study tests whether a daily dose of cannabidiol (CBD) can help people who smoke at least 5 cigarettes a day cut down or quit. It is for people staying at a treatment center in Los Angeles where cannabis use is not allowed.
North Hollywood, CaliforniaAges 18–65 - NCT05886582RecruitingPhase 2
Rotigotine patch added to therapy for cocaine use
This Phase 2 study tests whether a rotigotine skin patch, used alongside behavioral therapy, can help people reduce cocaine use. It also looks at changes in brain activity while you do study tasks.
Richmond, VirginiaAges 25–70 - NCT05658796Recruiting
Program to reduce opioid use after hip or knee replacement
This trial tests a support program called RXWell to help people use less opioid pain medicine after elective hip or knee replacement surgery. It may help by addressing anxiety and depression symptoms that can affect pain and recovery.
Monroeville, PennsylvaniaAges 18–100 - NCT05995535RecruitingPhase 2
Pregabalin and Lofexidine for Opioid Withdrawal
This study tests whether combining two medications, pregabalin and lofexidine, can help people stop using opioids by easing withdrawal symptoms. It's for adults who use opioids heavily and want to switch to a non-addictive blocker medication.
Baltimore, MarylandAges 18 years+ - NCT06636227RecruitingPhase 1
Diclofenac dose study for alcohol use disorder
This study tests whether different doses of diclofenac, an anti-inflammatory drug, can help people reduce heavy drinking. It looks at how the drug affects drinking patterns and overall health.
Catonsville, MarylandAges 21–65 - NCT05958017Recruiting
ReSET program to help stimulant use in HIV clinics
This study tests a care-support program called ReSET to improve adherence to treatment and reduce stimulant use for people living with HIV who are not currently in drug treatment. You may be offered support through HIV clinic care to help you stay on track, especially if you have access to a smartphone and stable housing.
Miami, FloridaAges 18–90
Hear when a new Opioid Use Disorder, Moderate trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for opioid use disorder, moderate?
- Yes. Clin2 currently lists 82 recruiting opioid use disorder, moderate studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a opioid use disorder, moderate trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a opioid use disorder, moderate trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.